Axsome Therapeutics AXSM Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$183.17M+36.2% | -$287.22M-20.1% | -$239.24M-27.8% | -$187.13M-43.5% | ||
| $503K-5.5% | $532K+15.9% | $459K+74.5% | $263K+246% | ||
| $93.75M+10.0% | $85.22M+36.1% | $62.62M+66.0% | $37.73M+81.3% | ||
| $84.78M+79.7% | $47.18M-17.4% | $57.12M— | —— | ||
| $10.66M— | —— | —— | —— | ||
| —— | $31.32M+1,410% | $2.07M-91.9% | $25.46M— | ||
| $83.74M+49.4% | $56.07M+53.8% | $36.45M-17.0% | $43.92M— | ||
| $6.38M-0.3% | $6.39M+0.3% | $6.38M+54.0% | $4.14M— | ||
| —— | -$422K-374% | $154K— | —— | ||
| $1.3M-50.6% | $2.64M+2.6% | $2.57M+73.6% | $1.48M+37.7% | ||
| -$94.45M+26.4% | -$128.41M+11.5% | -$145.08M-24.5% | -$116.51M-7.7% | ||
| $480K+77.8% | $270K-53.6% | $582K-17.1% | $702K+128% | ||
| -$480K-77.8% | -$270K+53.6% | -$582K+98.9% | -$53.7M-17,336% | ||
| —— | —— | —— | —— | ||
| $67.9M+66.5% | $40.78M-84.2% | $258.75M+6.1% | $243.76M+3,178% | ||
| $2.12M+115% | $990K— | —— | —— | ||
| $7.11M+79.9% | $3.95M+115% | $1.84M+245% | $532K— | ||
| $101.47M+75.4% | $57.84M-82.5% | $331.02M+16.3% | $284.58M+2,457% | ||
| —— | —— | —— | —— | ||
| $14.63M-25.7% | $19.69M+17.7% | $16.73M+118% | $7.69M+66.2% | ||
| $1.3M-50.6% | $2.64M+2.6% | $2.57M+73.6% | $1.48M+37.7% | ||
| $6.38M-0.3% | $6.39M+0.3% | $6.38M+54.0% | $4.14M— | ||
| -$2.47M-109% | $28.12M-42.5% | $48.92M+1,383% | $3.3M— | ||
| $503K-5.5% | $532K+15.9% | $459K+74.5% | $263K+246% | ||
| —— | —— | —— | —— | ||
| —— | -$422K-374% | $154K— | —— | ||
| $83.74M+49.4% | $56.07M+53.8% | $36.45M-17.0% | $43.92M— | ||
| —— | —— | $5.34M— | —— | ||
| $3.05M+119% | $1.39M-4.3% | $1.45M— | —— | ||
| $5.16M— | —— | -$3.69M— | —— | ||
| $2.12M+115% | $990K— | —— | —— | ||
| -$9.94M-26.4% | -$7.87M-26.6% | -$6.21M— | —— | ||
| $1.2M+46.7% | $816K— | —— | —— | ||
| $59.56M— | —— | —— | $6.25M— | ||
| $2.19M+111% | $1.03M— | —— | —— | ||
| —— | —— | —— | $45M— | ||
| $4.51M-15.8% | $5.36M— | —— | —— | ||
| —— | —— | $7.8M— | —— | ||
| —— | —— | —— | —— | ||
| -$94.87M+26.3% | -$128.68M+11.7% | -$145.66M-24.3% | -$117.21M-8.0% | ||
| -$94.87M+26.3% | -$128.68M+11.7% | -$145.66M-24.3% | -$117.21M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Axsome Therapeutics generate?
- Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
- What is Axsome Therapeutics's free cash flow?
- After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
- Where does Axsome Therapeutics's cash flow data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
